Microarray for Complex Chemotyping
Whether the application is biofuels, microbial ecological investigation or medical research, Lawrence Berkeley National Laboratory’s Berkeley Lab Multiplex Chemotyping Microarray
(MCM) has proven to be the most powerful and precise system for
investigations of biomass at the molecular level. MCM performs
rapid chemical analyses of prospective biofuel crops and microbial communities by combining high-throughput micro-contact
printing technology with high-fidelity vibrational spectroscopy and
mass spectrometry. Its ability to rapidly identify the chemical composition and biological function in plant and animal cells is unparalleled, as it can run up to 1,024 samples in 5 sec, compared with
just a few samples in the same period of time for competing technologies such as silicon microarray or UV-Vis
spectrometry. Multiplexing capabilities enable a throughput rate more than two-orders-of-magnitude beyond
existing methods, and precise deposition allows accurate detection of multiple chemicals within each sample.
Samples can include plant particles, airborne particulates, soil particles or microbes with sample volumes down
to 10 pL; and mixtures of proteins or heterogeneous biomolecules with dimensions smaller than 50 nm.
In biofuels applications, the MCM allows researchers to begin determining how specific genes control
cell-wall composition. In microbial community screening in medical research, MCM’s discovery of the deep
structure of fibrous protein aggregates have made MCM an essential part of the overall strategy for neutralizing the HIV infection.
◗ Lawrence Berkeley National Laboratory, www.lbl.gov
TB Be Gone
MDR-TB is a growing problem, estimated to kill
170,000 people annually and projected to infect
more than two million people between 2011 and
2015. Janssen Research & Development LLC’s
bedaquiline represents a significant scientific and
public health advancement in the treatment of
MDR-TB, as the first available medicine developed
specifically for pulmonary MDR-TB treatment.
Bedaquiline was discovered in the 1990s and
offers patients resistant to common TB drugs and
their health care providers with a new treatment
option. Current MDR-TB treatment is lengthy,
typically consisting of a two-year regimen with up
to six second-line drugs and, on average, less than
a 50% treatment success rate globally. Bedaquiline
brings new hope to MDR-TB patients as Phase
II clinical trials have demonstrated that adding
bedaquiline to current treatments decreased the
time to culture conversion and improved culture
conversion rates compared to placebo treatments.
Bedaquiline is a diarylquinoline antimycobacte-rial drug indicated as part of a combination therapy
in adults ( 18 years or older) with pulmonary MDR-TB (a form of TB that is characterized by resistance
to at least two of the four most powerful medicines
in today’s standard treatment regimen).
◗ Janssen Research & Development LLC
Reducing the Pain
Each year in the U.S., approximately 450,000 individuals sustain burns that
require medical attention. Over the past 10 years, the overall mortality rate for
burn injuries has decreased from 3. 4 to 2.7% for males and from 4. 6 to 3.3% for
females. While advances in medicine allow patients with burns of
larger total body surface area to survive, research shows that recovery
from burn injuries is incredibly painful and can be associated with
significant psychological consequences. Dressing changes, in particu-
lar, can be incredibly painful and cause considerable anxiety.
Milliken and Company’s ASSIST Silver is a low-adherent anti-
microbial dressing used primarily in burn care for the management
of skin grafts. The dressing incorporates three primary features:
Active Fluid Management (AFM) technology, an ionic silver antimicrobial and a low-adherent layer. AFM fab-
ric technology, a multi-layer, multi-component textile composite constructed as nylon Jersey knit with a poly-
ester lay-in on the graft contact side, helps maintain an optimal level of moisture at the graft site. The antimi-
crobial, SelectSilver, provides efficacy against a broad spectrum of wound pathogens. Finally, the low-adherent
layer reduces clinician time and minimizes adhesion to the graft. These features optimize ease-of-use for the
clinician and minimize patient pain, making ASSIST Silver a cost-effective treatment option for skin grafts.
◗ Milliken & Company, www.milliken.com
1416 E Southmore Ave
Pasadena, TX 77502
Respect the craft and it becomes a skill.
For three decades, CONSCI has crafted state-of-the-art gas analyses such as ppb and ppt
level volatile metal impurities in specialty
gases, trace impurities in hard to manage
samples such as metal hydrides, complex
mixtures and corrosive gases, as well as fast
and affordable routine impurity analyses. We
pride ourselves on our customer service and
unique solutions to analytical challenges.